| First author | Year | Intervention | Cancer type | Patients | Mean follow-up (months) | Data type |
| Yue [14] | 2014 | MVA | PTMC | 18 | 11.0 | VRR, VRR (12 months), CRR, ARR | Li [15] | 2018 | MVA | PTMC | 46 | 42.0 | VRR, VRR (12 months), CRR, ARR | Surg | PTMC | 46 | 42.0 | ARR | Li [16] | 2019 | MVA | PTMC | 168 | 25.1 | CRR, ARR | Surg | PTMC | 143 | 27.5 | ARR | Teng [17] | 2018 | MVA | PTMC | 15 | 36.0 | VRR, VRR (12 months), CRR, ARR | Teng D [18] | 2019 | MVA | PTMC | 185 | 20.7 | VRR, VRR (12 months), CRR, ARR | Yue [19] | 2020 | MVA | PTMC | 119 | 37.2 | VRR, VRR (12 months), CRR, ARR | Zhou [20] | 2020 | MVA | PTMC | 33 | 23.3 | VRR, VRR (12 months), CRR, ARR | LA | PTMC | 34 | 22.8 | VRR, VRR (12 months), CRR, ARR | Wang [21] | 2020 | MVA | PTMC | 107 | 15.1 | VRR, VRR (12 months), CRR | Ding [22] | 2019 | RFA | PTMC | 37 | 6.0 | VRR, VRR (12 months), CRR, ARR | Rong W [23] | 2020 | RFA | PTMC | 198 | 25.9 | VRR, VRR (12 months), CRR | Xiao [24] | 2020 | RFA | PTMC | 66 | 38.0 | VRR, VRR (12 months), CRR, ARR | Yan [25] | 2020 | RFA | PTMC | 414 | 42.15 | VRR, VRR (12 months), CRR, ARR | Yan Lb [26] | 2020 | RFA | PTMC | 211 | 24.4 | VRR, VRR (12 months), CRR, ARR | Zhang [27] | 2016 | RFA | PTMC | 92 | 7.8 | CRR, ARR | Zhang [28] | 2019 | RFA | PTMC | 30 | 18.0 | VRR, VRR (12 months), CRR, ARR | Zhou [29] | 2019 | LA | PTMC | 36 | 49.2 | ARR | Surg | PTMC | 45 | 48.5 | ARR | Ji [30] | 2019 | LA | PTMC | 37 | 16.5 | CRR, ARR |
|
|